Corvus Pharma Analyst Ratings
Corvus Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 150% | Cantor Fitzgerald | → $4 | Reiterates | Overweight → Overweight |
| 06/16/2023 | 118.75% | Mizuho | → $3.5 | Reiterates | Neutral → Neutral |
| 05/30/2023 | 525% | Ladenburg Thalmann | $4 → $10 | Maintains | Buy |
| 05/09/2023 | 150% | Cantor Fitzgerald | $2 → $4 | Maintains | Overweight |
| 03/30/2023 | 118.75% | Mizuho | → $3.5 | Reiterates | → Neutral |
| 10/07/2022 | 25% | Ladenburg Thalmann | → $2 | Initiates Coverage On | → Buy |
| 12/03/2021 | 400% | Cantor Fitzgerald | $5 → $8 | Maintains | Overweight |
| 12/01/2021 | 400% | Jefferies | → $8 | Initiates Coverage On | → Buy |
| 08/03/2021 | 118.75% | Mizuho | $4 → $3.5 | Maintains | Neutral |
| 07/16/2021 | 275% | HC Wainwright & Co. | $9.5 → $6 | Maintains | Buy |
| 05/27/2021 | 525% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 03/26/2021 | 493.75% | HC Wainwright & Co. | $12 → $9.5 | Maintains | Buy |
| 02/10/2021 | 150% | Mizuho | $7 → $4 | Downgrades | Buy → Neutral |
| 10/06/2020 | 650% | HC Wainwright & Co. | $10 → $12 | Maintains | Buy |
| 03/13/2020 | 400% | Wedbush | $11 → $8 | Maintains | Outperform |
| 03/10/2020 | 525% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 09/12/2019 | 337.5% | Mizuho | → $7 | Initiates Coverage On | → Buy |
| 05/29/2019 | 275% | Roth Capital | → $6 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/07/2023 | 150% | 坎託·菲茨傑拉德 | → 4 美元 | 重申 | 超重 → 超重 |
| 06/16/2023 | 118.75% | 瑞穗 | → 3.5 美元 | 重申 | 中性 → 中性 |
| 05/30/2023 | 525% | 拉登堡塔爾曼 | 4 美元 → 10 美元 | 維護 | 購買 |
| 05/09/2023 | 150% | 坎託·菲茨傑拉德 | 2 美元 → 4 美元 | 維護 | 超重 |
| 03/30/2023 | 118.75% | 瑞穗 | → 3.5 美元 | 重申 | → 中立 |
| 2022 年 7 月 10 日 | 25% | 拉登堡塔爾曼 | → 2 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 3 月 12 日 | 400% | 坎託·菲茨傑拉德 | 5 美元 → 8 美元 | 維護 | 超重 |
| 12/01/2021 | 400% | 傑富瑞 | → 8 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/03/2021 | 118.75% | 瑞穗 | 4 美元 → 3.5 美元 | 維護 | 中立 |
| 07/16/2021 | 275% | HC Wainwright & Co. | 9.5 美元 → 6 美元 | 維護 | 購買 |
| 05/27/2021 | 525% | 坎託·菲茨傑拉德 | → 10 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2021 年 3 月 26 日 | 493.75% | HC Wainwright & Co. | 12 美元 → 9.5 美元 | 維護 | 購買 |
| 2021 年 10 月 2 日 | 150% | 瑞穗 | 7 美元 → 4 美元 | 降級 | 買入 → 中性 |
| 2020 年 6 月 10 日 | 650% | HC Wainwright & Co. | 10 美元 → 12 美元 | 維護 | 購買 |
| 03/13/2020 | 400% | Wedbush | 11 美元 → 8 美元 | 維護 | 跑贏大盤 |
| 2020 年 10 月 3 日 | 525% | HC Wainwright & Co. | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2019 年 12 月 9 日 | 337.5% | 瑞穗 | → 7 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/29/2019 | 275% | 羅斯資本 | → 6 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Corvus Pharma (CRVS)?
Corvus Pharma（CRVS）的目標價格是多少？
The latest price target for Corvus Pharma (NASDAQ: CRVS) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $4.00 expecting CRVS to rise to within 12 months (a possible 150.00% upside). 6 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年9月7日公佈了Corvus Pharma（納斯達克股票代碼：CRVS）的最新目標股價。該分析公司將目標股價定爲4.00美元，預計CRVS將在12個月內上漲至150.00％（可能上漲150.00％）。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for Corvus Pharma (CRVS)?
Corvus Pharma（CRVS）的最新分析師評級是多少？
The latest analyst rating for Corvus Pharma (NASDAQ: CRVS) was provided by Cantor Fitzgerald, and Corvus Pharma reiterated their overweight rating.
Corvus Pharma（納斯達克股票代碼：CRVS）的最新分析師評級由坎託·菲茨傑拉德提供，Corvus Pharma重申了其增持評級。
When is the next analyst rating going to be posted or updated for Corvus Pharma (CRVS)?
Corvus Pharma（CRVS）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corvus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corvus Pharma was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Corvus Pharma的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Corvus Pharma的最新評級是在2023年9月7日提交的，因此你應該預計下一個評級將在2024年9月7日左右公佈。
Is the Analyst Rating Corvus Pharma (CRVS) correct?
分析師對Corvus Pharma（CRVS）的評級是否正確？
While ratings are subjective and will change, the latest Corvus Pharma (CRVS) rating was a reiterated with a price target of $0.00 to $4.00. The current price Corvus Pharma (CRVS) is trading at is $1.60, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的Corvus Pharma（CRVS）評級，目標股價爲0.00美元至4.00美元。Corvus Pharma（CRVS）目前的交易價格爲1.60美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。